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Endogenous interleukin-10 regulates Th1 responses that in- Murine interleukin (IL)-10 is a homodimeric, 57 amino
duce crescentic glomerulonephritis. acid cytokine that was initially known as “cytokine syn-
Background. Interleukin (IL)-10 plays a pivotal role in regu- thesis inhibitory factor” because of its ability to inhibit
lating the Th1/Th2 predominance of immune responses. Exoge-
cytokine production by T helper 1 (Th1) cells. IL-10 isnously administered IL-10 suppresses nephritogenic Th1 re-
produced by a number of cell types, including Th2 cells,sponses, inhibits macrophage function, and attenuates crescentic
glomerulonephritis (GN). To determine the role of endogenous and (at least in humans) by Th0 and Th1 cells [1]. Other
IL-10, the development of the nephritogenic immune response “immune cells,” such as macrophages and B cells, also
and crescentic GN was compared in IL-10–deficient (IL- produce IL-10, as do some “resident tissue” cells, includ-
102/2) and normal (IL-101/1) C57BL/6 mice.
ing keratinocytes and mesangial cells [2].Methods. GN was initiated in sensitized mice by the intrave-
Interleukin-10 is known to affect both cognate and in-nous administration of sheep antimouse glomerular basement
nate immune responses. It acts at a number of levels tomembrane globulin. Renal injury was evaluated 21 days later.
Results. Following the administration of anti-glomerular inhibit Th1 responses. In the context of antigen presenta-
basement membrane globulin, normal (IL-101/1) C57BL/6 tion, IL-10 inhibits major histocompatibility complex
mice developed proliferative GN with occasional crescents, (MHC) II expression [3], IL-12 production [4], and the
glomerular CD41 T-cell and macrophage accumulation, and
expression of some costimulatory molecules [5]. IL-10fibrin deposition. Using an identical induction protocol, IL-
inhibits interferon-g (IFN-g) production by Th1 cells102/2mice developed more severe GN. Crescent formation
both directly and via antigen-presenting cells. It has well-(IL-102/2, 23 6 2% of glomeruli; IL-101/1 , 5 6 2%), glomer-
ular CD41 T cells [IL-102/2, 1.0 6 0.2 cells per glomerular established, direct suppressive effects on macrophage
cross-section (c/gcs); IL-10 1/1, 0.3 6 0.05 c/gcs], glomerular functions [6], including inhibiting the production of tissue
macrophages (IL-102/2, 4.8 6 0.3 c/gcs; IL-10 1/1 , 1.7 6 factor [7] and cytokines, including tumor necrosis0.2 c/gcs), fibrin deposition [fibrin score (range 0 to 31); IL-
factor-a (TNF-a), IL-1, and migration inhibitory factor102/2, 1.10 6 0.04; IL-101/1 , 0.6 6 0.07], and serum creati-
[8, 9]. Paradoxically, in human monocytes, IL-10 in-nine (IL-102/2, 30 6 2 mmol/L; IL-10 1/1 , 23 6 1 mmol/L)
were all significantly increased in IL-102/2 mice (P , 0.05). creases CD64 (FcgRI) expression but has no effect on
Circulating antibody (IL-102/2, 1.05 6 0.16 OD units; IL- FcgRII or FcgIII [10]. IL-10’s capacity to increase CD64
101/1 , 0.63 6 0.08 OD units) and cutaneous delayed-type expression could theoretically increase macrophage-
hypersensitivity (skin swelling; IL-102/2, 0.21 6 0.03 mm; IL- mediated injury initiated by immune complexes.101/1 , 0.12 6 0.02 mm) to the nephritogenic antigen (sheep
Endogenous IL-10 can directly influence the functionglobulin) were also increased (both P , 0.05). Interferon-g
of cells that are effectors of and/or are affected by Th1production by cultured splenocytes was increased (IL-102/2
7.9 6 2.5 ng/4 3 106 cells, IL-101/1 0.28 6 0.09 ng/4 3 106 responses. IL-10 production by monocytes is up-regu-
cells, P , 0.05), but IL-4 production was unchanged. lated by lipopolysaccharide (LPS). Neutralization of
Conclusions. Endogenous IL-10 counter-regulates nephri- IL-10 increases TNF-a and IFN-g production and in-
togenic Th1 responses and attenuates crescentic GN.
creases mortality in experimental LPS-induced shock
[11], demonstrating that in this situation, IL-10 is
counter-regulatory (anti-inflammatory), rather than pro-Key words: T cell, macrophage, cytokines, delayed-type hypersensitiv-
ity, nephritogenic Th1 response, fibrin. inflammatory. The increased severity of cutaneous de-
layed-type hypersensitivity (DTH) [12] and experimen-Received for publication June 17, 1999
tal allergic encephalomyelitis (EAE) in IL-10–deficientand in revised form September 7, 1999
Accepted for publication September 9, 1999 mice [13] provides further evidence for the counter-regu-
latory role of endogenous IL-10. The absence of IL-10Ó 2000 by the International Society of Nephrology
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Table 1. Weight of normal (IL-101/1) and IL-10–deficientin experimental allogeneic cardiac transplantation re-
(IL-102/2) C57BL/6 mice
sults in accelerated graft loss [14], suggesting a role for
Male mice Female miceendogenous IL-10 in the protection from graft rejection.
IL-101/1 IL-102/2 IL-101/1 IL-102/2Interleukin-10 has been demonstrated in human glo-
merulonephritis (GN), in which both IL-10 mRNA and Pre-experiment (N 5 7) (N 5 5) (N 5 7) (N 5 4)
Range 16–22 14–18 14–18 14–16protein are found in the more severe glomerular lesions
Mean6SEM 17.761.1 16.461.0 16.660.7 15.060.6[15]. IL-10 mRNA has been detected in kidneys of rats
End of experiment
with accelerated anti-glomerular basement membrane Range 18–23 15–21 18–19 15–18
Mean6SEM 21.360.9 18.861.1b 18.360.2 16.760.6a(anti-GBM) GN [16]. The presence of IL-10 in this situa-
a P 5 0.02, b P 5 0.15 compared with IL-101/1 grouption may reflect activation of protective mechanisms in
the context of severe glomerular injury. The presence
of IL-10 mRNA has also been demonstrated in renal
tissue from rats during the heterologous phase of anti-
five male and four female IL-102/2 mice and sevenGBM antibody-induced injury, where it has been sug-
male and seven female IL-101/1 C57BL/6 mice. Allgested that it is linked to enhanced production of anti-
mice were six weeks old at the beginning of the experi-inflammatory eicosanoids [17].
ments. Their weights at the beginning and the end ofThe hypothesis that endogenous IL-10 counter-regu-
the experimental protocol are provided in Table 1.lates nephritogenic immune responses and affords pro-
tection against Th1-directed crescentic GN was ad- Histologic assessment of glomerular injury
dressed in an accelerated model of anti-GBM GN using
Glomerular crescent formation. Kidney tissue was fixedgene knockout IL-10–deficient mice and their wild-type
in Bouin’s fixative and embedded in paraffin, and 3 mmC57BL/6 controls. The histologic and functional renal in-
tissue sections were cut and stained with periodic acid-jury and the immune response to the nephritogenic anti-
Schiff (PAS). A glomerulus was considered to exhibitgen in the presence and absence of endogenous IL-10
crescent formation when two or more layers of cells werewere compared.
observed in Bowman’s space. Visceral epithelial cells
were considered to be part of the glomerular tuft and
METHODS were therefore not counted as part of a crescent. A
Mice minimum of 50 glomeruli was assessed to determine the
crescent score for each animal.Interleukin-10–deficient gene knockout mice were ob-
Glomerular T-cell and macrophage accumulation. Kid-tained from Dr. G. Karupiah (Canberra, Australia), with
ney tissue was fixed in periodate lysine paraformalde-permission from Dr. W. Mu¨ller (Cologne, Germany).
hyde for four hours, washed in 7% sucrose solution, andThe generation and phenotype of these mice have been
then frozen in liquid nitrogen. Tissue sections (6 mm)previously described [18], and the mice have been subse-
were stained to demonstrate CD41 cells and macro-quently back-crossed for nine generations onto a C57BL/6
phages using a three-layer immunoperoxidase technique,background. Homozygous IL-10–deficient mice (IL-
as previously described [20]. The primary monoclonal102/2) were bred from IL-102/2 males and heterozy-
antibodies were GK1.5 [antimouse CD4; American Typegous (IL-101/2) females and were selected by genotyp-
Culture Collection (ATCC), Manassas, VA, USA] anding using a polymerase chain reaction-based technique.
M1/70 (antimouse Mac-1; ATCC). A minimum of 20C57BL/6 IL-101/1 mice were used as controls. All mice
equatorially sectioned glomeruli were assessed per ani-bred were maintained under pathogen-free conditions
mal, and results were expressed as cells per glomerularat Monash University (Clayton, Victoria, Australia).
cross-section (c/gcs).
Induction of glomerulonephritis and Glomerular deposition of fibrin. Immunofluorescence
experimental design was performed on 4 mm cryostat cut tissue sections. Glo-
merular fibrin deposition was assessed on a minimumSheep antimouse GBM globulin was prepared as pre-
of 30 glomeruli per mouse using FITC-goat antimouseviously described [19]. To induce crescentic GN, mice
fibrin/fibrinogen serum (Nordic Immunological Labora-were sensitized by an injection of a total of 1 mg of
tories, Maidenhead, Berks) at a dilution of 1 in 20. Stain-sheep globulin in 100 mL of Freund’s Complete Adjuvant
ing was scored semiquantitatively on a scale of 0 to 31(Sigma Chemical Co., St. Louis, MO, USA) given subcu-
as follows: 0 5 no fibrin deposition, 1 5 fibrin occupyingtaneously in divided doses in each flank. Two days later,
up to one third of the glomerular cross-sectional area, 2 5GN was initiated by a single intravenous dose of sheep
fibrin occupying one third to two thirds of the glomeru-antimouse GBM globulin (1.25 mg/10 g body weight).
lus, and 3 5 greater than two thirds of the glomerularRenal injury was studied 21 days after the administration
of anti-GBM globulin. Experiments were performed in cross-section covered by fibrin.
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Assessment of glomerular deposition of sheep min in PBS for total immunoglobulin, IgG1, and IgG2b
assays or 2% casein in PBS for IgG2a and IgG3 assays.globulin, mouse immunoglobulin, and C3
Plates were washed and then incubated with mouse se-Sheep globulin was detected using FITC-conjugated
rum at the dilution indicated for one hour (or overnightrabbit antisheep IgG (Silenus, Hawthorn, Victoria, Aus-
at 48C for IgG2a and IgG3 assays) at 378C. Bound mousetralia) at a dilution of 1 in 1000, mouse immunoglobulin
immunoglobulin was detected with horseradish peroxi-using FITC-conjugated sheep antimouse immunoglobu-
dase-conjugated antibodies: sheep antimouse immuno-
lin (Silenus, Hawthorn) at a dilution of 1 in 100 and C3 globulin (1 in 2000; Amersham, Little Chalfont, UK) for
deposition using FITC-conjugated goat antimouse C3 total immunoglobulin and goat antimouse IgG1, IgG2a,
(Cappel, Durham, NC, USA) at a dilution of 1 in 50 IgG2b, or IgG3 (1 in 4000; Southern Biotechnology Assoc.,
on 4 mm cryostat cut tissue sections. The intensity of Birmingham, AL, USA) for IgG subclasses. ABTS (0.1
glomerular staining was scored semiquantitatively on a mol/L 2,29-azino-di-3-ethylbenzthiazoline sulfonate) was
scale of 0 to 31, with 0 being equivalent to background added as a chromogenic substrate, and the absorbence
and 31 equal to the most intense fluorescence in any read at 405 nm. Sera from six nonimmunized mice were
glomerulus. Glomerular deposition of mouse immuno- tested to provide normal controls.
globulin and C3 was also quantitated by determining Measurement of interferon-c and interleukin-4 produc-
the end point titer for detection using serial doubling tion by splenocytes. Spleens from mice with GN were re-
dilutions of these antibodies. The highest dilution of moved aseptically and placed in Dulbecco’s minimal Es-
detecting antibody at which staining above background sential medium (DMEM; ICN Biochemicals, Aurora, OH,
USA) containing 5% fetal calf serum (FCS; Trace Bio-levels could be detected was taken as the endpoint titer
sciences, Castle Hill, NSW, Australia). Single-cell sus-for each animal. Titers were determined for each animal
pensions were prepared, and erythrocytes were lyzed byand expressed as the log2.
incubation in 0.15 mol/L NH4Cl, 0.01 mol/L NaHCO3,
Assessment of renal function 0.1 mmol/L EDTA, pH 7.3, for one minute. Splenocytes
were washed in DMEM with 5% FCS and incubated atSerum was collected at the end of each experiment,
concentration of 4 3 106 cells/mL in DMEM with 10%and the creatinine concentrations were measured by the
FCS, 50 mmol/L 2-mercaptoethanol with protein G-puri-alkaline picric acid method. As serum creatinine is pro-
fied normal sheep IgG (10 mg/mL) in 48-well plates forportional to weight, and there was a significant difference
72 hours at 378C. Culture supernatants were collected forbetween the mean body weight of the IL-101/1 and
measurement of IFN-g and IL-4 by ELISA, as previously
IL-102/2mice, serum creatinine for IL-102/2 mice was described [22].
adjusted proportional to the ratio of the body weights
in the two groups at the end of the experiment, as pre- Statistical analysis
viously described [21]. Results are expressed as mean 6 sem, and the statisti-
cal significance of differences between groups was as-
Assessment of systemic immune responses sessed by the Mann Whitney U-test.
to sheep globulin
Cutaneous delayed-type hypersensitivity to sheep glob- RESULTS
ulin. Mice were challenged 24 hours prior to the end of
Endogenous interleukin-10 reduces the severity ofthe experiment by intradermal injection of sheep globu-
crescentic glomerulonephritislin [500 mg in 50 mL of phosphate-buffered saline (PBS)]
Genetically normal C57BL/6 (IL-101/1) mice devel-into the plantar surface of a hindfoot. An equivalent
oped proliferative GN with the accumulation of PAS1dose of irrelevant antigen (horse globulin) was injected
material (Fig. 1 A–C). Occasional crescentic glomeruliin the opposite foot pad as a control. Antigen-specific
were observed (Fig. 1D). Histologic appearances of GNfoot pad swelling was assessed 24 hours later by measur-
were more severe, and crescent formation was moreing the difference in thickness between the sheep globu-
frequent in IL-102/2mice (Fig. 1 E–H). Patchy perig-
lin and horse globulin injected sides in each mouse, using lomerular and tubulointerstitial inflammation was ob-
a micrometer. served, the severity of which paralleled the degree of
Serum antisheep globulin immunoglobulin and IgG sub- glomerular injury observed (Fig. 1 D, E, G, H). Quantita-
classes. Titers of total mouse antisheep globulin immu- tive analysis revealed significantly increased crescent for-
noglobulin and antisheep globulin, IgG1, IgG2a, IgG2b, mation in the absence of IL-10 (IL-101/1, 5 6 2% of
and IgG3 were measured by enzyme-linked immunosor- glomeruli; IL-102/2, 23 6 2%, P 5 0.0003; Fig. 2). The
bent assay (ELISA) on serum collected at the end of serum creatinine levels in IL-102/2 mice with GN, both
each experiment as previously described [19]. Plates before (26 6 1 mmol/L, P 5 0.02) and after adjustment
were coated with 10 mg/mL normal sheep globulin, for body weight (30 6 2 mmol/L, P 5 0.008) were signifi-
cantly increased compared to the levels in IL-101/1washed, and then blocked with 1% bovine serum albu-
Fig. 1. Histological appearances of glomerulonephritis (GN) in normal (IL-101/1) mice (A–D) and interleukin-10 (IL-10)–deficient (IL-102/2)
mice (E–H ) 21 days after anti-GBM globulin (PAS stain, magnification 3200). Under this protocol, genetically normal C57BL/6 mice (A2D)
developed proliferative GN with accumulation of PAS1 material in glomeruli. In a number of glomeruli, the parietal epithelial layer was cuboidal,
as is often found in murine glomeruli (small arrows, A and B). This was not considered to indicate glomerular crescent formation. However,
occasional crescents were noted in glomeruli (D, bold arrow). C57BL/6 mice deficient in IL-10 developed more severe glomerular injury, with
glomerular crescent formation in 23% of glomeruli (F2H, large arrows). Patchy interstitial injury was present and was centered around more
severely affected glomeruli (D2H).
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Fig. 2. Glomerular crescent formation and weight-adjusted serum cre-
atinine in normal (IL-101/1) and IL-10–deficient (IL-102/2) mice
with GN. The broken line represents the mean serum creatinine in
normal C57BL/6 mice. *P , 0.01; **P , 0.001.
Fig. 3. Effectors of cell mediated injury in normal (IL-101/1) and
IL-10–deficient (IL-102/2) mice with GN. In the absence of endoge-
nous IL-10, there was increased accumulation of CD41 T cells, macro-mice (23 6 1 mmol/L) (Fig. 2), indicating that the greater
phages in glomeruli and increased glomerular fibrin deposition. *P ,histologic severity of crescentic GN in IL-10–deficient
0.001; **P , 0.0001.
mice was associated with greater functional impairment.
The increased incidence of crescent formation in
IL-102/2 deficient mice was accompanied by increased
glomerular accumulation of effectors of DTH, including
CD41 cells (IL-101/1, 0.3 6 0.05 c/gcs; IL-102/2, 1.0 6 lenge with sheep globulin (antigen specific skin swelling;
0.2 c/gcs, P 5 0.0004), macrophages (IL-101/1, 1.7 6 IL-101/1, 0.12 6 0.02 mm; IL-102/2, 0.21 6 0.03 mm;
0.2 c/gcs; IL-102/2, 4.8 6 0.3 c/gcs, P , 0.0001) and
P 5 0.03; Fig. 4). IL-102/2 mice also developed higherfibrin, which was present predominantly in the glomeru-
serum levels of antigen-specific immunoglobulin thanlar tuft (fibrin score: IL-101/1, 0.6 6 0.07; IL-102/2,
IL-101/1 mice (Table 3). Analysis of the IgG subclasses1.1 6 0.04, P 5 0.0004; Fig. 3). Glomerular crescents were
showed a significant increase in the titer of IgG1 incomposed predominantly of parietal epithelial cells, with
IL-102/2 mice. However, there were no significant al-some macrophages and an occasional T cell (data not
shown). terations in the titers of Th1-associated IgG2a or IgG3
immunoglobulin subclasses between IL-101/1 and
Glomerular deposition of sheep globulin, mouse
IL-102/2 mice. IgG2b titers were also unaffected byimmunoglobulin, and complement were unaffected
IL-10 deficiency.by IL-10 deficiency
Linear deposition of sheep globulin, mouse immuno-
Endogenous interleukin-10 deficiency increasesglobulin, and complement was observed in glomeruli of
splenocyte interferon-g productionIL-101/1 and IL-102/2 mice with GN. There were no
differences between groups in the glomerular binding Splenocytes from IL-10–deficient mice developing GN
of any of these immune reactants whether assessed by showed strikingly enhanced IFN-g production following
fluorescence intensity or by the endpoint titer for detec- ex vivo stimulation with sheep globulin when compared
tion by fluorescence (Table 2). with splenocytes from normal mice with GN mice
(IL-101/1, 0.28 6 0.09 ng/mL; IL-102/2, 7.9 6 2.5Endogenous interleukin-10 deficiency increases
ng/mL; P 5 0.003). Splenoctye IL-4 production underantibody and delayed-type hypersensitivity responses
to sheep globulin the same conditions was no different in IL-101/1 (84 6
10 pg/mL) and IL-102/2(94 6 13 pg/mL) mice with GNCompared with IL-101/1 mice, IL-10–deficient mice
developed increased cutaneous DTH following chal- (Fig. 4).
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Table 3. Total antisheep globulin immunoglobulin and IgGTable 2. Glomerular deposition of sheep globulin, autologous
(mouse) antibody, and C3 in normal (IL-101/1) and subclasses in normal (non-immunized) mice and normal
(IL-101/1) and IL-10 deficient (IL-102/2) mice with GNIL-10 deficient (IL-102/2) mice with GN
IL-101/1 IL-102/2 Normal IL-101/1 IL-102/2
Total immunoglobulin 0.09460.010a 0.63260.080 1.04860.165bSheep globulin
Score (0 to 31) 2.160.2 1.960.3 IgG1 0.00960.006 0.69960.075 0.91160.070b
IgG2a 0.06360.034 0.17660.072 0.09660.021Autologous antibody
Endpoint positive titer 10.460.2a 10.560.3 IgG2b 0.01060.006 0.32560.060 0.25260.077c
IgG3 0.06060.030 0.14060.017 0.15060.036Score (0 to 31) 1.960.2 1.760.2
C3 a ELISA OD405Endpoint positive titer 10.360.2 10.160.3 b P 5 0.03
Score (0 to 31) 1.460.2 1.560.1 c P 5 0.15
a log2 of the end-point titer for detection by immunofluorescence
creased cutaneous DTH to the nephritogenic antigen,
but no detectable increase in autologous antibody or C3
deposition in glomeruli. Some tubulointerstitial inflam-
mation was observed in mice with GN, which reflected
the degree of glomerular injury observed and was quali-
tatively more severe in IL-102/2 mice.
Interleukin-10 has been shown to regulate both cog-
nate and noncognate immunity. IL-10 can inhibit Th1
responses at multiple levels and can either promote or
inhibit Th2 responses. In noncognate immune responses
such as those induced by endotoxemia [11] and thrombo-
sis [23] and in diseases involving cognate immune re-
sponses such as rheumatoid arthritis [24] and experimen-
tal autoimmune encephalomyelitis (EAE) [25], IL-10 has
been demonstrated to play a role as a counter-regulatory
cytokine. The demonstration of IL-10 in glomeruli of
patients with a variety of forms of GN, including severe
crescentic GN [15], indicates its participation in this dis-
ease but does not establish its functional role. The results
of these studies demonstrate that IL-10 plays a counter-
regulatory role by attenuating renal injury in experimen-
tal crescentic GN, consistent with its role in EAE and
rheumatoid arthritis.
A comparison of the immune responses to the nephri-
togenic antigen (sheep globulin) in IL-10–deficient and
Fig. 4. Systemic immune responses to sheep globulin in IL-101/1 and
normal mice provides some insights to the mechanismsIL-102/2 mice with GN. Skin DTH to sheep globulin was increased, as
was sheep globulin stimulated splenocyte IFN-g production. Splenocyte of IL-10’s counter-regulatory effects. Cutaneous DTH
IL-4 production was unchanged. *P 5 0.03; **P , 0.005. to sheep globulin was significantly increased in IL-10–
deficient mice. In keeping with this observation, effectors
of DTH, CD41 T cells, macrophages, and fibrin were
DISCUSSION also increased in glomeruli. It is likely that these alter-
ations indicate a heightened effector CD41 T-cell re-These studies demonstrate an important protective
sponse. Production of IFN-g by splenocytes stimulatedrole for endogenous IL-10 production in the develop-
with sheep globulin ex vivo was strikingly increased inment of cell-mediated crescentic glomerular injury initi-
IL-102/2 mice. IL-10–deficient mice have similar pro-ated by a planted glomerular antigen. IL-102/2 C57BL/6
portions of CD41 and CD81 cells in the spleens tomice, lacking the capacity to synthesize IL-10, developed
IL-101/1 mice; however, CD41 cells from spleens ofhistologically and functionally more severe crescentic
Nippostrongylus-infected IL-102/2 mice have beenGN than C57BL/6 mice capable of normal IL-10 syn-
shown to produce more IFN-g than genetically normalthesis. The exacerbation of renal injury observed in
mice [18]. It is likely that CD41 cells are the source ofIL-10–deficient mice was associated with increased accu-
mulation of the effectors of DTH in glomeruli and in- the increased IFN-g in IL-10–deficient mice, although it
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is not possible to exclude contributions from macro- tochemistry for type I and type IV did not reveal major
phages or CD81 cells. changes in collagen deposition in either the glomeruli
As IL-10 can directly suppress macrophage function or the interstitium (data not shown). However, using
(independent of T cells), some of the effects of IL-10 this disease induction protocol, there was only sparse
deficiency on crescentic GN may be due to an absence of deposition of collagen at day 21 in IL-101/1 mice, mak-
IL-10 induced down-regulation of macrophage effector ing significant differences difficult to detect in these
functions. Increased production of IFN-g may also directly studies.
augment macrophage activation in IL-102/2 mice and In murine anti-GBM–induced crescentic GN, the ad-
contribute to the increased glomerular injury. IFN-g– ministration of IL-10 prior to disease initiation diminished
deficient mice develop less severe glomerular injury in the nephritogenic Th1 response and attenuated crescentic
murine anti-GBM–induced crescentic GN [19]. Produc- GN [22]. Treatment with IL-10 after renal injury was
tion of cytokines such as TNF-a and IL-1 are also inhib- established also had significant beneficial effects in this
ited by IL-10 [12], and it is possible that effects on these model, particularly when combined with IL-4 [31]. In a
and other pro-inflammatory macrophage-derived cyto- passively induced, macrophage-dependent model of
kines may contribute to the exacerbation of renal injury anti-GBM GN in rats, the administration of IL-10 attenu-
in IL-10–deficient mice. ated glomerular injury and macrophage activation [32].
Interleukin-10–deficient mice developed increased se- However, in murine lupus, the inhibition of IL-10 delays
rum levels of antisheep globulin antibody, suggesting the onset of the systemic autoimmune response that
that IL-10 inhibits antibody production to this exogenous leads to the development of GN [33]. In these studies,
antigen. Surprisingly, there was an increase in the antigen where the nephritogenic immune response is directed
specific IgG1, a Th2-associated immunoglobulin sub- against a foreign antigen rather than occurring in the
class. No significant changes were observed in the Th1- context of systemic autoimmunity, endogenous IL-10 in-
associated subclasses, IgG2a and IgG3. This contrasts hibited rather than enhanced antibody production.
with the effects of IL-4 deficiency on IgG subclasses in In summary, these studies provide insights into the
crescentic GN [26]. IL-42/2mice developing this model role of endogenously produced IL-10 that increase our
of experimental GN show decreased antigen-specific understanding of its role in immune glomerular injury
IgG1 and increased IgG3 titers, consistent with a Th1 and support its potential therapeutic use at appropriate
shift of their humoral immune response. Thus, endoge- pharmacological doses. They demonstrate that endoge-
nous IL-10 inhibits Th1 cellular effector responses, but nous IL-10 attenuates cutaneous DTH and Th1-depen-
in contrast to endogenous IL-4, IL-10 does not shift the dent cell-mediated glomerular injury in experimental
humoral immune response toward a Th2 profile. These crescentic GN. They support an important role for this
findings are consistent with other studies using IL-102/2
cytokine in modulating immune glomerular injury and
mice [18]. IL-10 can affect antigen presentation by inhib-
highlight the need for a thorough understanding of theiting IL-12, the cytokine that establishes Th1 responses
Th1/Th2 predominance of the initiating immune re-[4, 13]. IL-12 has been shown to promote Th1 responses
sponse and the effector pathways involved in designingand the development of crescentic GN in this model
cytokine-based therapeutic strategies for modulating hu-[27]. In IL-10–deficient mice, increased IL-12 production
man GN.leading to enhanced Th1 effector responses and in-
creased production of IFN-g (and other Th1 cytokines)
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